Cytori Corporate Overview NASDAQ: CYTX

26th Annual Roth Conference

March 12, 2014

Safe Harbor Statement

This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All statements,

other than statements of historical fact, that address activities, events or developments that we intend, expect,

project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements

are based upon certain assumptions and assessments made by our management in light of their experience

and their perception of historical trends, current conditions, expected future developments and other factors

they believe to be appropriate.

The forward-looking statements included in this presentation involve known and unknown risks that relate to

Cytori’s future events or future financial performance and the actual results could differ materially from those

discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ

materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s Form

10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would

advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the

United States Securities and Exchange Commission for a more detailed description of these risks.

The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions

only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly

any forward-looking statements contained in this presentation as a result of new information, future events or

changes in Cytori’s expectations.

Cytori Investment Summary

Highlights

• Phase II U.S. heart failure trial

• U.S. government contract (BARDA) for thermal burns

• Pipeline of therapeutic indications from independent

studies

Adipose-derived cell therapy with device model

• Cardiovascular disease & soft tissue injury

• Product & contract revenue partially offsets cash burn

• Thousands of patients treated worldwide

Cytori Cell Therapy

Mechanisms

• Improve blood flow

• Modulate inflammation

• Wound healing

• Autologous

• Virtually ‘off the shelf’

• Multiple cell types = multiple mechanisms

System:

• Low six figure ASP

• Next-generation system COGS < $10,000

Per-procedure consumable:

• $8,000-$12,000 for vascular indications

• $2,000-$3,000 for soft tissue

• >80% GM

Cell therapies via proprietary device & single-use consumables =

Favorable pricing and margin opportunity

Cytori Cell Therapy:

Commercial Model & Economics

Therapeutic Focus

CARDIAC SOFT TISSUE COMMERCIAL

RESEARCH MARKET

• U.S. Phase II in CHF

• Long term data from CHF

and AMI trials in EU

• Burns: U.S. gov’t contract

worth up to $106 MM

• Hamstring injury: U.S. trial

• EU/Japan approvals

• Research sales

• 50+ studies completed,

ongoing or planned

Cardiac Cell Therapy

• Damage to the heart leads to

reduced function, heart failure

and death

• Current therapy does not

address damage to the heart

muscle

PRECISE Pilot Showed Proof-of-Concept

PRECISE TRIAL:

• 27 patient double-blind, randomized, placebo controlled European trial

• Intramyocardial injection using electromechanical mapping in area with

inducible ischemia

• 18 month data presented, publication in process

DATA SUMMARY:

Feasibility (Exercise Tolerance)

• VO2Max (maximum oxygen consumption): improvement (p<0.05

vs. placebo)

• METS (metabolic equivalent): improvement (p<0.05 vs. placebo)

Safety

• No safety issues

• Mortality [36 mo]: placebo 33%, ADRCs 14%

12

14

16

18

20

Baseline 6 months 18 months

VO

2 M

ax

Change in VO2Max at 6 and 18 Months

ADRCs

Placebo

PRECISE Pilot Trial: Exercise Tolerance

ATHENA I & II:

U.S. Ischemic Heart Failure Trials

• Prospective, double-blind, placebo-controlled trials

– ATHENA I: 45 patients, 2:1 randomization at lower dose

– ATHENA II: 45 patients, 2:1 randomization at higher dose

– Up to 10 centers

Development Pipeline

Ischemic

Heart

Failure Pilot Complete

U.S. Phase II

(ATHENA I & II)

Pivotal

2015

SAFETY

• Serious Adverse Events (SAEs)

• Arrhythmia assessment

• MACE (Cardiac Death or Hospitalization for Heart Failure)

EFFICACY

• VO2 Max (6 mo)

• LVEF, LVESV/LVEDV (6 mo)

• Perfusion defect (6 mo)

• Heart failure symptoms, angina, and quality of life (3, 6, 12 mo)

ATHENA I Endpoints

Ischemic Heart Disease: Market Dynamics

Ischemic heart disease in the United States

• Direct & indirect costs of heart failure estimated at $19.5B (2009)

• $11.7B paid to Medicare beneficiaries (2006)

• Medical costs of IHD expected to double 2013 to 2030

• Estimated incidence is 200,000 – 500,000 patients/year in the U.S. alone

Ischemic heart disease in Europe

• IHD expected to cost EU economies €60B/yr

• Estimated that 34.4M and 12.1M disability adjusted life years are lost in Europe

and the EU respectively each year due to IHD

Few, if any, new pharmaceutical approaches for IHD

Soft Tissue

• Thermal burns due to radiation injury

• Sports medicine (hamstring injury)

• Wound repair applications

BARDA Contract

Pre-Treatment 18 Mo. Post-Treatment Ex. Cytori Cell

Therapy in a chronic

thermal burn case

study

National preparedness grant worth up to $106 MM to develop

treatment for thermal burns combined with radiation injury

• In-Process Review anticipated in 1H2014 to determine if contract

options are awarded

• Contract options fully fund development from preclinical through FDA

PMA trial

• Cytori maintains commercial rights, possibility of government

procurement purchases

BARDA Development Pathway

Discussions

Begin

2010

Award

Announcement

Fall, 2012

3 Objectives Trigger

Option 1 & 3

Q1, 2014

3 Proof-of-concept Objectives

Ongoing

Cell viability

Animal model POC

Next Gen device feasibility

$32.6 M Option 1

$23.4M Option 3

Commercial Acquisition at

BARDA’s Discretion

$45.5M Option 2

Option 1 Objective

Triggers Option 2

Q4, 2015

Pre-Award, White Papers,

Proposal, Negotiation

$4.7M Phase 1 Proof of Concept

• Trial Design: – Part A: 10 patient open-label, safety, feasibility & dose-escalation

– Part B: 60 patient, double-blind, placebo-controlled safety, feasibility & dosing study

– Safety & functional end-points

16

U.S. RECOVER Trial: Hamstring Injury

Randomized, double-blind, placebo-controlled trial to evaluate

Cytori Cell Therapy for tears of the hamstring muscle

• Hamstring injuries are a persistent problem among elite and amateur athletes given the high incidence and recurrence rates, as well as the lengthy recovery time

• Broad range of indications, including:

• Ex: Chronic radiation wound case study in Japan

17

Wound Repair: Independent Research

Promising data from multiple independent research studies

- Cryptoglandular peri-anal fistula - Fistula post gastroenterological surgery

- Diabetic foot ulcer - Scleroderma in the hand

- Crohn’s fistula

Exposed Sacrum

1 Year Post Op Immediate Pre Op Intra Op, Debrided

90% cells to circular area

around sore

10% cells to sore itself

Intra Op, Post-Cell Rx

Commercial Research Market: Overview

• Targeted commercial sales ex-US to researchers

performing independently funded studies

• System and consumables sales generate commercial

revenue and gross margin

• Expands pipeline R&D to identify potential indications for

future development and partnering opportunities

Revenue Upside: Research Sales

• Targeted global commercial

sales

• Research customers under

international regulatory

approvals:

• Japan Class I clearance

• CE Mark vascular delivery

(Intravase®)

• New markets: Australia,

Singapore

Completed or ongoing studies Planned studies

Worldwide Investigator-Led Research

50+ studies worldwide completed, in process or planned

• Publications of independent

research using Cytori Cell Therapy

• Broad range of study indications

including:

• Stress urinary incontinence

• Scleroderma

• Hamstring injury

• ACL

• Parry Romberg syndrome

• Ischemic heart disease

Strategic Upside: Research Sales

• Outsources R&D for future pipeline indications

• Supports partnerships and other strategic

collaborations

• Ex: BARDA: U.S. government contract supported by Japanese

research radiation injury data and UK burn data

• Ex: Lorem Vascular: commercialization partnership based on

combination of Cytori clinical data and independent research data

Commercial Partnership: Lorem Vascular

Celution® System Commercialization Rights

Agreement Terms

• Newly formed company dedicated to Celution® products

• Australia, China, Hong Kong, Malaysia, & Singapore

• $24 million; 8 million shares at $3.00 per share

• Up to $500 million in commercial milestones

• Cytori receives transfer margin on long-term agreement

Global Intellectual Property

• 65 patents issued worldwide; 85 applications pending

• Cover current & future Celution® Systems, methods, use of

adipose-derived regenerative cells for soft tissue, cardiac and

pipeline indications

29%

15%

7%

33%

16%

Geographic Distribution

U.S.

Japan

Europe

Asia-Pacific - Other

Other

41%

23%

18%

18%

Patent Type

Devices - Current/Next-Gen

Cardiovascular

Reconstructive Surgery

Pipeline Therapies

Financials

Current Select Data

Cash $24.5 MM (pro forma as of 12/31/13)

Senior Term Loan $27 MM (Matures 2017)

Shares

Outstanding

75 MM

Warrants

Outstanding

8.6MM @$2.63

(7.6 MM expire by Sept 2014)

Upcoming Milestones

CARDIOVASCULAR

– Complete enrollment in the U.S. ATHENA trial

– Report six-month outcomes from the U.S. ATHENA trial

– Publish PRECISE chronic ischemic heart failure trial long-term data

SOFT TISSUE

– BARDA decision for potential contract expansion

– Initiate enrollment in U.S. trial (Part A) for hamstring injury

COMMERCIAL RESEARCH SALES

– Growth in product & contract sales in 2014

– Achieve product registration for the Celution® System in China

Cytori Investment Summary

Highlights

• Phase II U.S. heart failure trial

• U.S. government contract (BARDA) for thermal burns

• Pipeline of therapeutic indications from independent

studies

Adipose-derived cell therapy with device model

• Cardiovascular disease & soft tissue injury

• Product & contract revenue partially offsets cash burn

• Thousands of patients treated worldwide

Cytori Corporate Overview NASDAQ: CYTX

Thank you!